Avanir Pharmaceuticals Inc

Avanir Pharmaceuticals — Technical Presentation (August 2009)

31 slides from Avanir Pharmaceuticals's technical presentation, Aug 11, 2009

  1. Slide 1: STAR Trial Results Conference Call August 11, 2009

    STAR Trial Results Conference Call August 11, 2009

  2. Slide 2: Forward-looking Statement

    Forward-looking Statement This presentation contains forward-looking statements concerning future events and performance of our Company. These statements can be identified by words or phrases such as, "believe," "expect," "will," and "may". Readers are cautioned against placing reliance on these for

  3. Slide 3: Avanir Participants

    3 Keith Katkin ^ President and Chief Executive OfficerRandall Kaye, MD ^ Chief Medical Officer Avanir Participants

  4. Slide 4: Summary of STAR Trial Results

    Summary of STAR Trial Results Zenvia(tm) 30/10 mg met its primary endpoint demonstrating efficacy in the treatment of pseudobulbar affect (PBA)Zenvia(tm) 20/10 mg also met the secondary analysis of the primary endpoint demonstrating efficacy in the treatment of pseudobulbar affect (PBA)Both doses of

  5. Slide 5: PBA Market Overview

    PBA Market Overview Keith Katkin

  6. Slide 6: PBA Clinical Overview

    PBA Clinical Overview Neurologic disorder causing involuntary emotional outburstsCrying, laughing or other emotional displaysAssociated with numerous neurologic diseases or injuriesAlzheimer's disease Amyotrophic lateral sclerosis (ALS)Multiple sclerosis (MS)Parkinson's diseaseStrokeTraumatic brain

  7. Slide 7: PBA: A Significant Health Burden

    (CHART) PBA: A Significant Health Burden SF-36 Health Status Survey Scores * Significant differences at p<.051 PBA Burden of Illness Study, Avanir Pharmaceuticals - data on file 2 US norms reported for select chronic conditions - data on file 3 PBA Burden of Illness Study - patients without PBA symp

  8. Slide 8: U.S. PBA Market

    U.S. PBA Market U.S. PBA Populations1 U.S. PBA Populations1 Market Characteristics Estimated 2 million in U.S. with moderate / severe PBA1No approved PBA therapiesLow physician satisfaction with off-label treatments2Concentrated prescriber base appropriate for a small specialty sales force 8 Approxi

  9. Slide 9: STAR Trial Results

    STAR Trial Results Randall Kaye, MD

  10. Slide 10: Confirmatory Phase III STAR Trial

    Confirmatory Phase III STAR* Trial 10 * The Safety, Tolerability And Efficacy Results of AVP-923 in PBA Randomized n = 107 n = 326 Placebo BID Zenvia 30/10 mg BID n = 110 n = 109 Zenvia 20/10 mg BID PopulationsMS (n=129)ALS (n=197)Primary EndpointCrying / Laughing RatesSecondary EndpointsCNS-LS scor

  11. Slide 11: STAR Trial - Efficacy Endpoints

    STAR Trial - Efficacy Endpoints 11 Endpoint Description PBA Episode Rate (primary endpoint) Changes from baseline in laughing/crying episodes rates recorded in the patient diary Center for Neurologic Study - Lability Scale (CNS-LS) A 7 question validated scale that provides a score for total PBA int

  12. Slide 12: Demographics

    Demographics 12 Avanir data on file Characteristic Zenvia 30/10 n = 110 Zenvia 20/10 n = 107 Placebo n = 109 Mean Age, years (SD) 53.1 (11.0) 50.8 (11.1) 50.3 (11.9) Gender Male 46 (41.8%) 53 (49.5%) 50 (45.9%) Female 64 (58.2%) 54 (50.5%) 59 (54.1%) Race Caucasian 80 (72.7%) 80 (74.8%) 83 (76.1%) B

  13. Slide 13: Baseline Characteristics

    Baseline Characteristics 13 Avanir data on file Characteristic Zenvia 30/10 n = 110 Zenvia 20/10 n = 107 Placebo n = 109 Mean PBA episodes/day (SD) 4.7 (9.5) 6.8 (12.9) 4.5 (7.6) Mean PBA episodes/week 32.6 47.3 31.2 Mean Baseline CNS-LS score (SD) 19.8 (4.9) 21.0 (5.0) 19.9 (4.7) Underlying Disease

  14. Slide 14: Patient Disposition

    Patient Disposition 14 Avanir data on file Baseline Characteristic Zenvia 30/10 n = 110 Zenvia 20/10 n = 107 Placebo n = 109 Subjects Dosed 107 (97.3%) 102 (95.3%) 106 (97.2%) Completed Study 100 (90.9%) 88 (82.2%) 94 (86.2%) Discontinued 9 (8.2%) 19 (17.8%) 15 (13.8%) Adverse Event (AE) 1 (0.9%) 5

  15. Slide 15: Treatment Effect

    Treatment Effect Treatment Effect Significant Efficacy 15 Both the Zenvia 30/10 mg and 20/10 mg significantly reduced PBA episodes Avanir data on file Over the course of the study, both Zenvia 30/10 mg and Zenvia 20/10 mg demonstrated a significant reduction in PBA episode rates when compared to pla

  16. Slide 16: Primary Endpoint: Reduction of PBA Episodes

    Primary Endpoint: Reduction of PBA Episodes Reduction of PBA Episodes Reduction of PBA Episodes 16 At week 12 (end of study), patients receiving Zenvia 30/10 mg reported a mean reduction of 88% from baseline PBA episode rates Avanir Data on File PBA Episode Rates Over Time by Treatment Group P < 0.0

  17. Slide 17: Primary Endpoint: Reduction of PBA Episodes

    Primary Endpoint: Reduction of PBA Episodes Reduction of PBA Episodes Reduction of PBA Episodes 17 Zenvia 30/10 mg and Zenvia 20/10 mg provided a statistically significantly reduction of PBA episode rates over the course of the study compared to placebo Avanir Data on File Reduction in PBA Episode R

  18. Slide 18: Secondary Endpoint: Improvements in CNS-LS Score

    Secondary Endpoint: Improvements in CNS-LS Score CNS-LS Score1 CNS-LS Score1 Significant Efficacy 18 Zenvia 30/10 mg decreased the intensity and severity of PBA Zenvia 30/10 mg demonstrated a significantly greater decrease in CNS-LS score compared to placebo (p=0.0002)Zenvia 20/10 mg demonstrated a

  19. Slide 19: Secondary Endpoint: Improvements in CNS-LS Score

    Secondary Endpoint: Improvements in CNS-LS Score Improvements in CNS-LS Score Improvements in CNS-LS Score 19 Zenvia 30/10 mg decreased the intensity and severity of PBA Avanir Data on File CNS-LS Scores Over Time by Treatment Group * P ^0.001 for Zenvia 30/10 mg vs. placebo at each visit * * * * **

  20. Slide 20: Safety Summary Analysis of Adverse Events

    Safety 20 Summary Analysis of Adverse Events (AEs) Avanir data on file Adverse Event Zenvia 30/10 n = 107 Zenvia 20/10 n = 102 Placebo n = 106 Number of AEs 334 286 295 Patients with at least one AE 89 (83.2%) 82 (80.4%) 86 (81.1%) Patients who discontinued due to an AE 4 (3.7%) 8 (7.8%) 2 (1.9%) Pa

  21. Slide 21: Adverse Events by Treatment Group

    Adverse Events 21 AEs ^ 5% - by Treatment Group Avanir data on file Adverse Event Zenvia 30/10 n = 107 Zenvia 20/10 n = 102 Placebo n = 106 Falls 22 (20.6%) 14 (13.7%) 21 (19.8%) Dizziness 20 (18.7%) 11 (10.8%) 6 (5.7%) Headache 15 (14.0%) 15 (14.7%) 16 (15.1%) Nausea 14 (13.1%) 8 (7.8%) 10 (9.4%) D

  22. Slide 22: Serious Adverse Events

    Serious Adverse Events 38 SAEs occurred in 27 patients over the course of the studySeven deaths occurred in the study, all in the ALS populationThree deaths were reported in the 30/10 mg group, three in the 20/10 mg group and one in the placebo groupFive of the deaths (four in the Zenvia treatments

  23. Slide 23: Cardiovascular Safety

    Cardiovascular Safety 23 Avanir data on file* Percent of EKGs taken over the course of the study Analysis of Central Tendency Zenvia 30/10 Zenvia 20/10 Placebo Mean QT - Baseline (QTcB/QTcF) 418.3 / 407.0 416.2 / 403.8 415.9 / 404.8 Mean QT - Day 84 (QTcB/QTcF) 420.8 / 411.6 413.2 / 404.6 416.9 / 40

  24. Slide 24: Safety Summary

    Safety Summary Both doses of Zenvia were generally safe and well toleratedThe most commonly reported adverse events that appeared to be more frequent than in placebo were dizziness, nausea and diarrheaBoth doses of Zenvia demonstrated a satisfactory safety profileNo clinically meaningful changes in

  25. Slide 25: Conclusions

    Conclusions Top-line STAR data indicate that the new Zenvia 30/10 mg dose offers:Statistically significant and clinically meaningful efficacyAn improved tolerability and safety profile compared to the previous formulationWe expect that the full STAR trial dataset, combined with additional clinical a

  26. Slide 26: Next Steps

    Next Steps Keith Katkin AVANIR pharmaceu ticals

  27. Slide 27: Comparison of Product Profiles

    Comparison of Product Profiles 27 Based on the STAR top-line data and the Advanced Cardiac Safety Study, Zenvia 30/10 mg appears to offer an improved risk / benefit balance 1 STAR trial - Avanir data on file; end of study compared to baseline2 Avanir studies 99-AVR-102 (ALS) and 02-AVR-106 (MS) Char

  28. Slide 28: Zenvia 30/10: An Enhanced Regulatory Package

    Zenvia 30/10: An Enhanced Regulatory Package The Zenvia PBA clinical program features an extensive databaseOver 30 pre-clinical and clinical studies spanning a 10 year periodThe complete response filing will feature a >95% increase in the number of subjects compared to the 2006 NDA839 subjects expos

  29. Slide 29: PBA Program Timeline

    PBA Program Timeline 29 2009 Last patient in - Phase III STAR trial in PBA Top-line results - Phase III STAR trial in PBAFull Double blind STAR data presented at scientific meetingOpen label safety study in PBA completed ? 2010 Full response to PBA approvable letterFDA approval decision on PBA appli

  30. Slide 30: Zenvia PBA Program Summary

    Zenvia PBA Program Summary 30 Large market opportunityNo competitionSignificant unmet medical need Commercialization Improved overall risk-benefitData to address approvable letterEnhanced regulatory package Regulatory Strong top-line resultsSignificant clinical efficacyImproved safety and tolerabili

  31. Slide 31: Q&A Session

    Q&A Session All AVANIR pharmaceu ticals

Avanir Pharmaceuticals — Technical Presentation (August 2009) on 6ix